Abstract

Integral outer membrane proteins (OMPs) are crucial for the maintenance of the proteobacterial envelope permeability barrier to some antibiotics and detergents. In Enterobacteria, envelope stress caused by unfolded OM proteins (OMPs) activates the sigmaE (σE) transcriptional response. σE upregulates OMP-biogenesis factors, including the b-barrel assembly machinery (BAM) that catalyzes OMP folding. Here we report that DolP (formerly YraP), a σE-upregulated and poorly understood OM lipoprotein, is crucial for fitness in cells that undergo envelope stress. We demonstrate that DolP interacts with the BAM complex by associating to OM-assembled BamA. We provide evidence that DolP is important for proper folding of BamA that overaccumulates in the OM, thus supporting OMP biogenesis and OM integrity. Notably, mid-cell recruitment of DolP had been linked to regulation of septal peptidoglycan remodelling by an unknown mechanism. We now reveal that, during envelope stress, DolP loses its association with the mid-cell, thereby suggesting a mechanistic link between envelope stress caused by impaired OMP biogenesis and the regulation of a late step of cell division.

Data availability

All data generated and analysed during this study are available in the manuscript and supporting files. Source data related to the CRISPRi screen are provided in the supporting files.

Article and author information

Author details

  1. David Ranava

    Laboratory of Microbiology and Molecular Genetics, CNRS, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5841-7699
  2. Yiying Yang

    Laboratory of Microbiology and Molecular Genetics, CNRS, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Luis Orenday-Tapia

    Laboratory of Microbiology and Molecular Genetics, CNRS, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1134-0823
  4. François Rousset

    Microbiology Department, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Catherine Turlan

    Laboratory of Microbiology and Molecular Genetics, CNRS, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Violette Morales

    Laboratory of Microbiology and Molecular Genetics, CNRS, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  7. Lun Cui

    Microbiology Department, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  8. Cyril Moulin

    Laboratory of Microbiology and Molecular Genetics, CNRS, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Carine Froment

    Institute of Pharmacology and Structural Biology, CNRS, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  10. Gladys Munoz

    Laboratory of Microbiology and Molecular Genetics, CNRS, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  11. Jérôme Rech

    Laboratory of Microbiology and Molecular Genetics, CNRS, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  12. Julien Marcoux

    Institute of Pharmacology and Structural Biology, CNRS, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7321-7436
  13. Anne Caumont-Sarcos

    Laboratory of Microbiology and Molecular Genetics, CNRS, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  14. Cécile Albenne

    Laboratory of Microbiology and Molecular Genetics, CNRS, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  15. David Bikard

    Synthetic Biology Laboratory, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5729-1211
  16. Raffaele Ieva

    Laboratory of Microbiology and Molecular Genetics, CNRS, Toulouse, France
    For correspondence
    raffaele.ieva@univ-tlse3.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3405-0650

Funding

Centre National de la Recherche Scientifique (ATIP-Avenir)

  • Raffaele Ieva

Agence Nationale de la Recherche (ANR-10-INBS-08)

  • Julien Marcoux

Agence Nationale de la Recherche (ANR-10-LABX-62-IBEID)

  • David Bikard

Fondation pour la Recherche Médicale (PostDoc Fellowship)

  • David Ranava

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Ranava et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,714
    views
  • 420
    downloads
  • 21
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. David Ranava
  2. Yiying Yang
  3. Luis Orenday-Tapia
  4. François Rousset
  5. Catherine Turlan
  6. Violette Morales
  7. Lun Cui
  8. Cyril Moulin
  9. Carine Froment
  10. Gladys Munoz
  11. Jérôme Rech
  12. Julien Marcoux
  13. Anne Caumont-Sarcos
  14. Cécile Albenne
  15. David Bikard
  16. Raffaele Ieva
(2021)
Lipoprotein DolP supports proper folding of BamA in the bacterial outer membrane, promoting fitness upon envelope stress
eLife 10:e67817.
https://doi.org/10.7554/eLife.67817

Share this article

https://doi.org/10.7554/eLife.67817

Further reading

    1. Immunology and Inflammation
    2. Microbiology and Infectious Disease
    Benita Martin-Castaño, Patricia Diez-Echave ... Julio Galvez
    Research Article

    Coronavirus disease 2019 (COVID-19) is a respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that displays great variability in clinical phenotype. Many factors have been described to be correlated with its severity, and microbiota could play a key role in the infection, progression, and outcome of the disease. SARS-CoV-2 infection has been associated with nasopharyngeal and gut dysbiosis and higher abundance of opportunistic pathogens. To identify new prognostic markers for the disease, a multicentre prospective observational cohort study was carried out in COVID-19 patients divided into three cohorts based on symptomatology: mild (n = 24), moderate (n = 51), and severe/critical (n = 31). Faecal and nasopharyngeal samples were taken, and the microbiota was analysed. Linear discriminant analysis identified Mycoplasma salivarium, Prevotella dentalis, and Haemophilus parainfluenzae as biomarkers of severe COVID-19 in nasopharyngeal microbiota, while Prevotella bivia and Prevotella timonensis were defined in faecal microbiota. Additionally, a connection between faecal and nasopharyngeal microbiota was identified, with a significant ratio between P. timonensis (faeces) and P. dentalis and M. salivarium (nasopharyngeal) abundances found in critically ill patients. This ratio could serve as a novel prognostic tool for identifying severe COVID-19 cases.

    1. Epidemiology and Global Health
    2. Microbiology and Infectious Disease
    Bo Zheng, Bronner P Gonçalves ... Caoyi Xue
    Research Article

    Background:

    In many settings, a large fraction of the population has both been vaccinated against and infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Hence, quantifying the protection provided by post-infection vaccination has become critical for policy. We aimed to estimate the protective effect against SARS-CoV-2 reinfection of an additional vaccine dose after an initial Omicron variant infection.

    Methods:

    We report a retrospective, population-based cohort study performed in Shanghai, China, using electronic databases with information on SARS-CoV-2 infections and vaccination history. We compared reinfection incidence by post-infection vaccination status in individuals initially infected during the April–May 2022 Omicron variant surge in Shanghai and who had been vaccinated before that period. Cox models were fit to estimate adjusted hazard ratios (aHRs).

    Results:

    275,896 individuals were diagnosed with real-time polymerase chain reaction-confirmed SARS-CoV-2 infection in April–May 2022; 199,312/275,896 were included in analyses on the effect of a post-infection vaccine dose. Post-infection vaccination provided protection against reinfection (aHR 0.82; 95% confidence interval 0.79–0.85). For patients who had received one, two, or three vaccine doses before their first infection, hazard ratios for the post-infection vaccination effect were 0.84 (0.76–0.93), 0.87 (0.83–0.90), and 0.96 (0.74–1.23), respectively. Post-infection vaccination within 30 and 90 days before the second Omicron wave provided different degrees of protection (in aHR): 0.51 (0.44–0.58) and 0.67 (0.61–0.74), respectively. Moreover, for all vaccine types, but to different extents, a post-infection dose given to individuals who were fully vaccinated before first infection was protective.

    Conclusions:

    In previously vaccinated and infected individuals, an additional vaccine dose provided protection against Omicron variant reinfection. These observations will inform future policy decisions on COVID-19 vaccination in China and other countries.

    Funding:

    This study was funded the Key Discipline Program of Pudong New Area Health System (PWZxk2022-25), the Development and Application of Intelligent Epidemic Surveillance and AI Analysis System (21002411400), the Shanghai Public Health System Construction (GWVI-11.2-XD08), the Shanghai Health Commission Key Disciplines (GWVI-11.1-02), the Shanghai Health Commission Clinical Research Program (20214Y0020), the Shanghai Natural Science Foundation (22ZR1414600), and the Shanghai Young Health Talents Program (2022YQ076).